<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7018675</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">31786651</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">7018675</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">5382</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1007/s00213-019-05382-1</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Subject demographics and clinical measures</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Subject demographics and clinical measures</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Demographic and clinical statistics</th><th>Participants (<italic>N</italic> = 17)</th></tr></thead><tbody><tr><td>Age, years</td><td>41.28 (11.23)</td></tr><tr><td>Gender, female/male</td><td>3/14</td></tr><tr><td>Handedness, right/left</td><td>17/0</td></tr><tr><td>PANSS–positive</td><td>12.69 (4.37)</td></tr><tr><td>PANSS–negative</td><td>14.05 (3.96)</td></tr><tr><td>PANSS–general</td><td>23.37 (6.40)</td></tr><tr><td>PANSS–total</td><td>50.12 (12.91)</td></tr><tr><td>Antipsychotic medication–Ol/Ri/Ar/Pa/Ha/Zu/Fl</td><td>7/4/2/2/1/1/1</td></tr></tbody></table><table-wrap-foot><p>Data are reported as mean (standard deviation)</p><p><italic>PANSS</italic> Positive and Negative Syndrome Scale scores, <italic>Ar</italic> aripiprazole, <italic>Fl</italic> flupentixol, <italic>Ha</italic> haloperidol, <italic>Ol</italic> olanzapine, <italic>Pa</italic> paliperidone, <italic>Ri</italic> risperidone, <italic>Zu</italic> zuclopenthixol</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Subject demographics and clinical measures</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Demographic and clinical statistics</th><th>Participants (N = 17)</th></tr></thead><tbody><tr><td>Age, years</td><td>41.28 (11.23)</td></tr><tr><td>Gender, female/male</td><td>3/14</td></tr><tr><td>Handedness, right/left</td><td>17/0</td></tr><tr><td>PANSS–positive</td><td>12.69 (4.37)</td></tr><tr><td>PANSS–negative</td><td>14.05 (3.96)</td></tr><tr><td>PANSS–general</td><td>23.37 (6.40)</td></tr><tr><td>PANSS–total</td><td>50.12 (12.91)</td></tr><tr><td>Antipsychotic medication–Ol/Ri/Ar/Pa/Ha/Zu/Fl</td><td>7/4/2/2/1/1/1</td></tr></tbody></table></div>Data are reported as mean (standard deviation)PANSS Positive and Negative Syndrome Scale scores, Ar aripiprazole, Fl flupentixol, Ha haloperidol, Ol olanzapine, Pa paliperidone, Ri risperidone, Zu zuclopenthixol</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Reductions in resting state functional connectivity following administration of 2400 mg N-acetylcysteine compared to placebo in the Default Mode (DMN) and Salience networks (SN) in patients with schizophrenia. Node and Montreal Neurological Institute (MNI) coordinates of regions of interest with significant p values (FDR corrected, controlling for multiple comparisons).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p>Reductions in resting state functional connectivity following administration of 2400 mg N-acetylcysteine compared to placebo in the Default Mode (DMN) and Salience networks (SN) in patients with schizophrenia. Node and Montreal Neurological Institute (MNI) coordinates of regions of interest with significant <italic>p</italic> values (FDR corrected, controlling for multiple comparisons).</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Node and MNI coordinate</th><th>Network</th><th><italic>p</italic> FDR</th><th><italic>t</italic> statistic</th></tr></thead><tbody><tr><td rowspan="2"><p>Medial prefrontal cortex (1, 55, − 3)–mid frontal gyrus (− 38, 18, 42)</p><p>Anterior cingulate cortex (0, 22, 35)–frontal pole (26, 52, 8)</p></td><td>DMN</td><td>0.04</td><td><italic>t</italic> (16) = − 4.75</td></tr><tr><td>SN</td><td>0.01</td><td><italic>t</italic> (16) = − 5.51</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Reductions in resting state functional connectivity following administration of 2400 mg N-acetylcysteine compared to placebo in the Default Mode (DMN) and Salience networks (SN) in patients with schizophrenia. Node and Montreal Neurological Institute (MNI) coordinates of regions of interest with significant p values (FDR corrected, controlling for multiple comparisons).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Node and MNI coordinate</th><th>Network</th><th>p FDR</th><th>t statistic</th></tr></thead><tbody><tr><td rowspan="2">Medial prefrontal cortex (1, 55, − 3)–mid frontal gyrus (− 38, 18, 42)Anterior cingulate cortex (0, 22, 35)–frontal pole (26, 52, 8)</td><td>DMN</td><td>0.04</td><td>t (16) = − 4.75</td></tr><tr><td>SN</td><td>0.01</td><td>t (16) = − 5.51</td></tr></tbody></table></div></transformed-table></extracted-table></extracted-tables-set>